Abstract library

12 results for "Rufini".
#142 The role of 18F DOPA-PET in a case of malignant pheochromcytoma
Introduction: Pheocromocytoma is a rare tumor arising from chromaffin cells of adrenal medullary or extra adrenal paraganglionic tissue. Histological criteria cannot differentiate benign from malignant pheocromocytomas. The diagnosis of a malignant pheocromocytoma requires local invasion, recurrence and documented metastatic disease. The radionuclide scanning (123I - 131I-MIBG) is a fundamental diagnostic tool used to confirm the biochemical and radiological diagnosis of pheochromocytoma. In fact, MIBG scanning may confirm that the visualised lesion in an adrenal gland is indeed a pheochromocytoma and detect extra-adrenal paraganglionic tissue. However, MIBG scans are negative in around 15% of benign pheochromocytomas and in up to 50% of malignant ones. Other radionuclide techniques (18FDG-PET, 18F-DOPA-PET, 18F-FDA-PET) have been successfully used in investigation of pheochromocytomas. 18F-DOPA-PET and 18F-FDA-PET have been reported to be highly sensitive and specific for benign pheochromocytomas, while 18FDG-PET can be useful for malignant lesions with higher metabolic activity.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof. Laura De Marinis
#201 Comparison of 18F-DOPA, 68Ga-Somatostatin Analogues and 18F-FDG PET-CT in Patients with Recurrent Medullary Thyroid Carcinoma
Introduction: Various PET tracers have been proposed for detection of recurrent disease in medullary thyroid carcinoma (MTC). No data have been reported comparing 18F-DOPA and 68Ga-somatostin analogues (SA) in MTC.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Giorgio Treglia
#351 Comparison of 68Ga-Somatostatin Analogues, 18F-DOPA and 18F-FDG PET/CT in Patients with Recurrent Medullary Thyroid Carcinoma
Introduction: Early detection of recurrences is a crucial step in the management of patients (pts) with medullary thyroid carcinoma (MTC). Currently, there is growing interest for PET tracers in MTC such as: 18F-FDG (reflecting glucose metabolism), 18F-DOPA (reflecting amine decarboxylation), 68Ga-somatostatin analogues (reflecting somatostatin receptors expression)
Conference:
Category: Basic
Presenting Author: Dr. Giorgio Treglia
#484 Diagnostic Accuracy of Gallium-68 Somatostatin Receptor Positron Emission Tomography in Patients with Thoracic and Gastroenteropancreatic Neuroendocrine Tumors: A Meta-Analysis
Introduction: Gallium-68 somatostatin receptor (SMSR) positron emission tomography (PET) is a valuable diagnostic tool for patients with neuroendocrine tumors (NET). To date, a meta-analysis about the diagnostic accuracy of this functional imaging method is lacking.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Giorgio Treglia
#545 A Case of ACTH-Secreting Bronchial Carcinoid
Introduction: Ectopic ACTH syndrome (EAS) occurs in about 5-10% of ACTH-dependent hypercortisolism and, in up to 15% of cases, is related to occult neoplasms.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof Laura De Marinis
#580 Diagnostic Performance of Dual Tracer PET/CT in Staging Neuroendocrine Tumors of the Lung
Introduction: Different positron emission tomography/computed tomography (PET/CT) tracers may be useful in staging lung neuroendocrine tumors (LNETs)
Conference:
Category: Clinical
Presenting Author: Dr. Giorgio Treglia
#589 Pancreatic neuroendocrine tumors and Diffusion weighted MRI: a better tool for detection?
Introduction: Pancreatic neuroendocrine tumors (pNETs) are often difficult to detect because of small size. Because surgery is curative in localized pNETs, preoperative localization is necessary.
Conference:
Category: Clinical
Presenting Author: Miss Alessandra Farchione
#619 Diagnostic Accuracy of F-18-DOPA PET or PET/CT in Neuroendocrine Tumors: A Meta-Analysis
Introduction: A specific feature of NETs is amine precursor uptake and decarboxylation; this is the rationale for using PET with F-18-DOPA, a cathecholamine precursor, in diagnosis of NETs.
Conference: 10th Annual ENETS Conference (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Barbara Muoio
Authors: Muoio B, Treglia G, Rufini V, ...
#987 Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional MRI in Pancreatic Neuroendocrine Tumors and Comparison with 68Ga-DOTANOC PET/CT
Introduction: Pancreatic neuroendocrine tumors (pNETs) are often difficult to detect because of small size and have variable prognosis related to grading and staging.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr. Maria Gabriella Brizi
#1907 Pancreatic Neuroendocrine Tumors in MEN1 Disease: A Monocentrice Longitudinal and Prognostic Study
Introduction: In MEN1+ patients (MEN+), pNETs are considered to be high risk for multiple, malignant and aggressive tumors.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: md Sabrina Chiloiro
Keywords: pNETs, MEN, prognosis